AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19781431
Drug: Norepinephrine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine dose
Trial: 10713296
Drug: Saccharin (23.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharin (23.7 mg)
Trial: 9377617
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg/d for 7 days followed by 0.8 mg/d for 7 days)
Trial: 31402223
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.5% plain bupivacaine (100 mg) plus 20 mL liposomal bupivacaine (266 mg)
Trial: 31402223
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL 0.25% plain bupivacaine (100 mg)
Trial: 24799482
Drug: PET-negative residues
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-negative residues after chemotherapy (548 patients)
Trial: 22443921
Drug: Manual compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual compression with hemostatic patch
Trial: 22443921
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (manual compression with and without hemostatic patch)
Trial: 20185734
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (OI) - 300 units combined with 400 mg of delivery agent orally
Trial: 20185734
Drug: Subcutaneous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous regular human insulin (RHI) - 15 units
Trial: 18602250
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements containing 60 mg of iron and 250 microg of folic acid plus 25 mg of zinc
Trial: 18602250
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements containing 60 mg of iron and 250 microg of folic acid
Trial: 11465711
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (specific treatments not detailed)
Trial: 8158065
Drug: Saphenous patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous patch (Group B)
Trial: 8158065
Drug: Prosthetic Gore-Tex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosthetic Gore-Tex patch (Group C)
Trial: 2895124
Drug: Residual antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual antibacterial activity with chlorhexidine gel
Trial: 26073754
Drug: HDM extract
RxNorm normalized name: American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDM [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM extract (active) administered orally twice daily for 12 months
Trial: 26073754
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered orally twice daily for 12 months
Trial: 19590194
Drug: Amitriptyline 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 37.5 mg twice daily for 14 days (pilot study)
Trial: 19590194
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg once daily for 28 days (phase II study)
Trial: 19590194
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg once daily for 28 days (phase II study)
Trial: 19590194
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg once daily for 28 days (phase II study)
Trial: 15253827
Drug: 11 mL
RxNorm normalized name: camphor 0.11 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mL of cold anesthetic gel (group 1)
Trial: 15253827
Drug: Plain lubricating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain lubricating gel (group 2)
Trial: 15253827
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel (group 3)
Trial: 9243105
Drug: Fasting immunoreactive
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting immunoreactive insulin
Trial: 9243105
Drug: Proinsulin/specific insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin/specific insulin ratio
Trial: 9243105
Drug: Specific insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specific insulin
Trial: 9243105
Drug: Proinsulin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinsulin and proinsulin/specific insulin ratio
Trial: 9243105
Drug: High proinsulin/specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High proinsulin/specific insulin ratio
Trial: 8440766
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg nicotine per day
Trial: 8440766
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg nicotine per day
Trial: 8440766
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine per day
Trial: 8440766
Drug: Nicotine Transdermal
RxNorm normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Transdermal System 21 mg/day
Trial: 8440766
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of Nicotine Transdermal System 7 mg/day plus 14 mg/day
Trial: 29584456
Drug: Avelumab in
RxNorm normalized name: avelumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab in combination with pegylated liposomal doxorubicin
Trial: 28857740
Drug: Double-blind drug
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind drug reduction programme leading to full withdrawal within 6 months.
Trial: 28857740
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control group maintained baseline level of medication).
Trial: 11071974
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - Oral conjugated oestrogen (0.625 mg) + medroxyprogesterone acetate (2.5 mg) daily for 12 weeks
Trial: 8450327
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous nicardipine
Trial: 334808
Drug: Phenytoin 100
RxNorm normalized name: phenytoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 100 mg
Trial: 29720244
Drug: Taurolidine-citrate lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine-citrate lock solution
Trial: 26463420
Drug: Mandibular Advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular Advancement Therapy (MAD)
Trial: 23158856
Drug: Hydrocortisone 100
RxNorm normalized name: hydrocortisone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 100 mg intravenous, 3 times/day for 7 days
Trial: 20627914
Drug: Bronchodilators (salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators (salbutamol plus ipratropium)
Trial: 19097963
Drug: Meperidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.4 mg/kg
Trial: 16177972
Drug: Echinilin (Echinacea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinilin (Echinacea purpurea) administered at onset of cold for 7 days, 5 mL/dose on day 1 and 3 doses on subsequent days
Trial: 16177972
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at onset of cold for 7 days
Trial: 12952843
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) for 3 days (GTN+ARB group)
Trial: 12952843
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg/d) for 3 days (GTN group)
Trial: 12952843
Drug: Placebo skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo skin patches and placebo tablets for 3 days (control group)
Trial: 12952843
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg/d) (GTN group)
Trial: 12952843
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) (GTN+ARB group)
Trial: 9892314
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of glycine (N=9)
Trial: 10829989
Drug: Malnourished children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malnourished children with hypoalbuminemia (serum albumin < 2.5 g/dl)
Trial: 10829989
Drug: Malnourished children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malnourished children with anemia (hemoglobin < or = 8.0 g/dl)
Trial: 6625248
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg . kg‐1 and fentanyl 6 micrograms . kg‐1 (Group M)
Trial: 6625248
Drug: Thiopentone 6
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 6 mg . kg‐1 and fentanyl 5 micrograms . kg‐1 (Group T)
Trial: 29041916
Drug: Coordinated rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordinated rehabilitation programme with early onset of patient participation and intensified occupational therapy and physiotherapy after hip fracture surgery.
Trial: 23766611
Drug: Intralesional Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Steroids
Trial: 12081605
Drug: Thymosin-alpha1 and
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin-alpha1 and famciclovir combination therapy
Trial: 12081605
Drug: Famciclovir monotherapy
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Famciclovir monotherapy
Trial: 2024560
Drug: Droperidol (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.03 mg.kg‐1 to 0.25 mg.kg‐1) with fentanyl
Trial: 30764731
Drug: Angiography-based machine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiography-based machine learning (ML) algorithm
Trial: 27046461
Drug: levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.25% + tramadol 1 mg/kg
Trial: 27046461
Drug: levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.25% + tramadol 2 mg/kg
Trial: 26435060
Drug: Glucose consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose consumption (25% of daily energy requirements)
Trial: 26435060
Drug: Fructose consumption
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose consumption (25% of daily energy requirements)
Trial: 26435060
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose corn syrup (HFCS) consumption (25% of daily energy requirements)
Trial: 26788345
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 600 mg
Trial: 19762734
Drug: 1.0 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL/kg of 0.225% ropivacaine (low volume/high concentration, LVHC)
Trial: 15551194
Drug: Olanzapine (OLA)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLA) 5-20 mg/d
Trial: 15551194
Drug: Flupenthixol (FLU)
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (FLU) 5-20 mg/d
Trial: 10658681
Drug: IL-2 +
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 + G-CSF mobilization
Trial: 10658681
Drug: G-CSF mobilization
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF mobilization alone (Control)
Trial: 3935466
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (Nitroderm TTS 5)
Trial: 29117472
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (weekly messages for 22 weeks) in addition to healthy lifestyle counselling
Trial: 21046932
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of OROS hydromorphone once daily
Trial: 21046932
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of immediate-release hydromorphone four times daily
Trial: 18561878
Drug: Prophylactic Implantable
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy
Trial: 16525182
Drug: Conventional radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, photodynamic therapy
Trial: 16525182
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery of chemotherapy
Trial: 16525182
Drug: New experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New experimental therapies such as immunotherapy
Trial: 12411282
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 0.12, 0.9, or 7% saline
Trial: 12411282
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with amiloride followed by inhalation of 0.12 and 0.9% saline
Trial: 12411282
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with amiloride and inhalation of 7% saline
Trial: 12411282
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of vehicle (0.12% saline)
Trial: 11074391
Drug: Topical growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical growth factors (particularly platelet-derived growth factor)
Trial: 11074391
Drug: Topical ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketanserin
Trial: 11074391
Drug: Systemic hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic hyperbaric oxygen therapy
Trial: 8975251
Drug: newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: newly developed film‐coated tablet with sustained release
Trial: 8975251
Drug: reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reference formulation
Trial: 1310572
Drug: Foscarnet induction
RxNorm normalized name: foscarnet Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet induction therapy at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days.
Trial: 1310572
Drug: Foscarnet maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet maintenance therapy at a dosage of 90 mg/kg/day via 2-hour infusion.
Trial: 1310572
Drug: Foscarnet treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet treatment delayed until the first signs of retinitis progression (Control group).
Trial: 7398735
Drug: Microencapsulated digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microencapsulated digoxin capsules (0.38 mg)
Trial: 7398735
Drug: Commercial tablets
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial tablets (ultrarapidly dissolving)
Trial: 31444589
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg enfortumab vedotin (Arm A)
Trial: 31444589
Drug: 1.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg enfortumab vedotin (Arm B)
Trial: 31444589
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of enfortumab vedotin
Trial: 21857489
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation group (deferred ART)
Trial: 18254574
Drug: Prednisolone oral
RxNorm normalized name: prednisolone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone oral solution + placebo tablets + procaterol MDI
Trial: 18254574
Drug: Prednisolone tablets
RxNorm normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone tablets + placebo oral solution + procaterol MDI
Trial: 14568892
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg)
Trial: 2097565
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg b.i.d. e.v.) starting from the day before the operation and continuing for the following seven days
Trial: 2097565
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5,000 IU b.i.d. by s.c. route) from day 0 to the 7th post-operative day
Trial: 31912787
Drug: Frozen gloves
RxNorm normalized name: GLOVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen gloves (FGs) worn on both hands during chemotherapy
Trial: 2393206
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg four times daily for 2 days
Trial: 7032370
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal solution (300 micrograms/day)
Trial: 28068956
Drug: Beta-lactam/macrolide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam/macrolide combination
Trial: 25788197
Drug: LAM 100
RxNorm normalized name: midazolam 100 MG in 100 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM 100 mg daily
Trial: 25788197
Drug: ADF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADF 10 mg daily
Trial: 21414565
Drug: aliskiren/amlodipine/HCTZ (300/10/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aliskiren/amlodipine/HCTZ (300/10/25 mg)
Trial: 21414565
Drug: aliskiren/amlodipine (300/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aliskiren/amlodipine (300/10 mg)
Trial: 19153265
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aliskiren and Losartan
Trial: 9063541
Drug: Powdered HSA
RxNorm normalized name: 125 I HSA
DrugBank: Albumin iodinated I-125 serum (DB09429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered HSA charcoal (2,000 m2/g)
Trial: 9063541
Drug: Low-surface-area (LSA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-surface-area (LSA) charcoal (950 m2/g)
Trial: 8095006
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 3 ng min-1kg-1
Trial: 8095006
Drug: Glucagon infusion
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon infusion at 6 ng min-1kg-1
Trial: 8095006
Drug: Octreotide pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide pretreatment (0.8 microgram/kg subcutaneously) before insulin infusion
Trial: 8095006
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during hypoglycaemia
Trial: 26757788
Drug: LY3015014 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3015014 300 mg every 4 weeks (Q4W)
Trial: 26757788
Drug: LY3015014 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3015014 300 mg every 8 weeks (Q8W)
Trial: 12648985
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy with propranolol (with or without isosorbide‐5‐mononitrate [ISMN])
Trial: 1582601
Drug: Nicardipine 3
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 3 mg
Trial: 23036478
Drug: AG200-15 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 patch (highest dose)
Trial: 23036478
Drug: Lowest-dose patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest-dose patch